scholarly journals Case Report: Convalescent Plasma, a Targeted Therapy for Patients with CVID and Severe COVID-19

2020 ◽  
Vol 11 ◽  
Author(s):  
Karel F. A. Van Damme ◽  
Simon Tavernier ◽  
Nele Van Roy ◽  
Elisabeth De Leeuw ◽  
Jozefien Declercq ◽  
...  
Keyword(s):  
Case Report ◽  
Targeted Therapy ◽  
Therapeutic Strategy ◽  
Clinical Course ◽  
Disease Course ◽  
Viral Shedding ◽  
Clinical Recovery ◽  
Immunodeficiency Disorder ◽  
Optimal Therapeutic Strategy ◽  
Common Variable

The disease course of COVID-19 in patients with immunodeficiencies is unclear, as well as the optimal therapeutic strategy. We report a case of a 37-year old male with common variable immunodeficiency disorder and a severe SARS-CoV-2 infection. After administration of convalescent plasma, the patient’s condition improved rapidly. Despite clinical recovery, viral RNA remained detectable up to 60 days after onset of symptoms. We propose that convalescent plasma might be considered as a treatment option in patients with CVID and severe COVID-19. In addition, in patients with immunodeficiencies, a different clinical course is possible, with prolonged viral shedding.

scholarly journals Prolonged Duration of Viral Shedding of SARS-CoV-2: A Case Report

2020 ◽  
Vol 4 (4) ◽  
pp. 509-512
Author(s):  
Brandon Fong ◽  
Kory London
Keyword(s):  
Case Report ◽  
Clinical Course ◽  
The Body ◽  
Disease Course ◽  
Hypoxemic Respiratory Failure ◽  
Viral Shedding ◽  
Viral Particles ◽  
Prolonged Duration ◽  
Multiple Strains

Introduction: The literature on the clinical course of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) suggests patients continue shedding viral particles typically for an average of 20 days until the body builds immunity against the infection. However, a few cases have shown prolonged duration in viral shedding and highlight the significant increased mortality in these patients. It has also been suggested that multiple strains of SARS-COV-2 exist, keying the possibility to reinfection. Case Report: We present a case of a 57-year-old male who presented twice over 37 days with symptoms related to SARS-COV-2, and only on his second visit was found to be in hypoxemic respiratory failure and cardiogenic shock. He also reportedly had a period of convalescence in between presentations. Discussion: This case highlights the still unclear disease course of SARS-COV-2 and the need for diligence in providing strong follow-up instructions and evaluation for sequelae of the infection.

scholarly journals Common Variable Immunodeficiency (CVID) with Granulomatous Interstitial Lung Disease (GLILD) and SARS COVID-19 Infection: Case Report and Review of Literature

2021 ◽  
Author(s):  
Debendra Pattanaik ◽  
Shaunah Ritter ◽  
Joseph Fahhoum
Keyword(s):  
Case Report ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Common Variable Immunodeficiency ◽  
Clinical Course ◽  
Pneumococcal Vaccination ◽  
Severe Infection ◽  
Ivig Therapy ◽  
Ivig Treatment ◽  
Common Variable

Abstract Background We present a case of CVID complicated by granulomatous interstitial lung disease (GLILD). This patient clinical course was further complicated by COVID-19 infection. This is only the 2nd known case report of COVID 19 in CVID with GLILD. The clinical course and outcome of COVID 19 infection with common variable immunodeficiency (CVID) and GLILD is not well known. Case presentation: Our patient met the clinical features of CVID secondary to low IgG/IgA, recurrent infections, and failure to respond to pneumococcal vaccination. He was treated with monthly maintenance IVIG therapy. Our patient also was diagnosed with co-existing GLILD that despite IVIG treatment was progressing. The patient needed to be started on Rituxan and Mycophenolate Mofetil to achieve control but unfortunately became infected with COVID19 delaying his treatment for GLILD. Our patient only suffered from mild COVID 19 infection and was able to make antibodies to this. We believe severe infection was avoided as his CVID was well controlled with IVIG therapy despite progression of his granulomatous interstitial lung disease. Conclusion In conclusion, our patient with CVID with co-existing biopsy proven granulomatous interstitial lung disease despite being very high risk for severe COVID 19 infection only had mild infection. This was believed to be due to well controlled CVID with IVIG therapy.

Recurrent Pneumonias and Bronchiectasis - Is it an Immunodeficiency Disorder? - A Case Report

2020 ◽  
Vol 40 (2) ◽  
pp. 139-142
Author(s):  
Sumit Agrawal ◽  
S Shreeram ◽  
A Jha ◽  
B Prajapati
Keyword(s):  
Case Report ◽  
Past History ◽  
Pulmonary Infections ◽  
Primary Immunodeficiency Disorder ◽  
Recurrent Pneumonia ◽  
Immunodeficiency Disorder ◽  
History Of ◽  
Autoimmune Cytopenias ◽  
Common Variable ◽  
Low Serum

Common Variable Immunodeficiency (CVID) is a form of primary immunodeficiency disorder characterised by hypogammaglobulinemia and recurrent sino-pulmonary infections. Its diagnosis is based on the presence of low serum IgG (< 2 SD below normal for age) with or without low IgA/ IgM levels and presentation beyond two years of age. These children also have disorders of autoimmunity with majority of them presenting as autoimmune cytopenias, predominantly thrombocytopenia and some having anaemia and neutropenias. Here we report a nine years old boy with past history of recurrent pneumonia, presenting this episode with fungal pneumonia, thrombocytopenia and anaemia eventually diagnosed as CVID.

scholarly journals Common variable immunodeficiency (CVID) with granulomatous interstitial lung disease (GLILD) and SARS COVID-19 infection: case report and review of literature

2021 ◽  
Vol 17 (1) ◽  
Author(s):  
Debendra Pattanaik ◽  
Shaunah Ritter ◽  
Joseph Fahhoum
Keyword(s):  
Case Report ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Common Variable Immunodeficiency ◽  
Clinical Course ◽  
Pneumococcal Vaccination ◽  
Severe Infection ◽  
Ivig Therapy ◽  
Ivig Treatment ◽  
Common Variable

Abstract Background We present a case of CVID complicated by granulomatous interstitial lung disease (GLILD). This patient clinical course was further complicated by COVID-19 infection. This is only the 2nd known case report of COVID 19 in CVID with GLILD. The clinical course and outcome of COVID 19 infection with common variable immunodeficiency (CVID) and GLILD is not well known. Case presentation Our patient met the clinical features of CVID secondary to low IgG/IgA, recurrent infections, and failure to respond to pneumococcal vaccination. He was treated with monthly maintenance IVIG therapy. Our patient also was diagnosed with co-existing GLILD that despite IVIG treatment was progressing. The patient needed to be started on Rituxan and Mycophenolate mofetil to achieve control but unfortunately became infected with COVID19 delaying his treatment for GLILD. Our patient only suffered from mild COVID 19 infection and was able to make antibodies to this. We believe severe infection was avoided as his CVID was well controlled with IVIG therapy despite progression of his granulomatous interstitial lung disease. Conclusion In conclusion, our patient with CVID with co-existing biopsy proven granulomatous interstitial lung disease despite being very high risk for severe COVID 19 infections only had mild infection. This was believed to be due to well controlled CVID with IVIG therapy.

Chylopericardium following Atrial Septal Defect Repair: Case Report

2005 ◽  
Vol 8 (1) ◽  
pp. 23 ◽  
Author(s):  
Sanjay Kumar ◽  
Bharati Sinha
Keyword(s):  
Case Report ◽  
Atrial Septal Defect ◽  
Cardiac Tamponade ◽  
Unusual Case ◽  
Septal Defect ◽  
Clinical Course ◽  
Defect Repair ◽  
Cardiac Operations

Chylopericardium after intrapericardial cardiac operations is extremely rare. We present an unusual case of postoperative chylopericardium with cardiac tamponade following atrial septal defect repair, and we comment on the clinical course and treatment.

Sign in / Sign up

Export Citation Format

Share Document